03 Feb 2022 Awareness raising

New analysis reveals the stark disparities in cancer rates between ethnic groups

Cancer Research UK has published a new analysis of cancer rates by ethnicity in England, providing crucial data on how some cancer rates vary by ethnicity.

The results were published in the British Journal of Cancer and reveal stark disparities in cancer rates between different ethnic groups.

The study demonstrates the importance of understanding the differences and inequalities in cancer and to highlight where improvements in survival, treatment and care can be made.

Given the renewed focus on the health of minority ethnic groups in the UK during the COVID-19 pandemic, where these groups were disproportionately affected, it is important to now focus on how improvements can be made in relation to cancer diagnosis and treatment. It presents an opportunity for improvements in both policy and practice.

Fiona Hazell, Chief Executive of Leukaemia UK, said:

“We welcome this study and the insights it provides. Addressing health inequalities in cancer prevention, early diagnosis and treatment must be a priority for the UK Government. The 10-year cancer plan provides one opportunity to achieve this but leukaemia and other blood cancers must be included if we’re to improve and save the lives of those affected.

We also encourage the government to support the NHS in ensuring that more ethnicity data is collected so trends like this can be spotted, and interventions made, as soon as possible.”

The study shows that Black people are almost three times more likely to get myeloma. It also shows that Asian people are amongst the most likely to get leukaemia.

Both leukaemia and myeloma are types of blood cancer. Blood cancer is the 5th most common type of cancer and the 3rd biggest cause of cancer deaths in the UK. Further research is vital to improve survival rates as well as the quality of life for those who receive this devastating diagnosis.

With all cancers and across all ethnic groups, awareness of the signs and symptoms is vital to drive improvements in diagnosis, effective treatment and survival.

Fiona Hazell, Chief Executive of Leukaemia UK, added:

“Early diagnosis is key to effective treatment and improving survival from blood cancers. Symptoms such as headaches, fatigue, unusual bruising or bleeding, should not be ignored – and a blood test is vital to achieving an early diagnosis. Don’t hesitate to talk to your GP if you are concerned that you may be experiencing these symptoms.”

Related posts

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

7 November 2022

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…

Leukaemia UK appoints Hannah Peckham as newest Ambassador

16 November 2023

Leukaemia UK appoints Hannah Peckham as newest Ambassador

Leukaemia UK has today announced its appointment of award-winning children’s book author, Hannah Peckham, as its newest celebrity Ambassador. Hannah joins the likes of actor Dougray Scott, celebrity chef Francesco…

The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care

8 July 2025

The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care

The Best Practice Timed Pathway We’re delighted to share that Leukaemia UK, in partnership with Lymphoma Action and Myeloma UK, is working with the NHS England Cancer programme team to…

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

25 August 2020

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.